Symbols / CNSP $2.33 +3.10% CNS Pharmaceuticals, Inc.
CNSP Chart
About
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, develops anti-cancer drug candidates for the treatment of brain and central nervous system (CNS) tumors. The company's drug candidates include TPI 287 and Berubicin, which are in Phase 2 clinical trial for the treatment of glioblastoma and other CNS malignancies. It has license agreement with Cortice Biosciences, Inc. The company was incorporated in 2017 and is headquartered in Houston, Texas.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 1.34M |
| Enterprise Value | -8.43M | Income | -13.07M | Sales | — |
| Book/sh | 17.25 | Cash/sh | 15.90 | Dividend Yield | — |
| Payout | 0.00% | Employees | 4 | IPO | — |
| P/E | 0.00 | Forward P/E | -5.97 | PEG | — |
| P/S | — | P/B | 0.14 | P/C | — |
| EV/EBITDA | 0.64 | EV/Sales | — | Quick Ratio | 5.04 |
| Current Ratio | 5.82 | Debt/Eq | 0.31 | LT Debt/Eq | — |
| EPS (ttm) | -35.75 | EPS next Y | -0.39 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-31 16:00 | ROA | -85.59% |
| ROE | -197.11% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 574.58K |
| Shs Float | 523.81K | Short Float | 6.03% | Short Ratio | 1.17 |
| Short Interest | — | 52W High | 34.80 | 52W Low | 2.06 |
| Beta | 0.46 | Avg Volume | 48.22K | Volume | 19.95K |
| Target Price | $10.00 | Recom | None | Prev Close | $2.26 |
| Price | $2.33 | Change | 3.10% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$10.00
Mean price target
2. Current target
$2.32
Latest analyst target
3. DCF / Fair value
$-370.73
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.32
Low
$10.00
High
$10.00
Mean
$10.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-09-12 | up | Maxim Group | Hold → Buy | $20 |
| 2025-03-25 | down | Maxim Group | Buy → Hold | — |
- CNS Pharma shifts from single cancer focus to hunting new brain and tumor drugs - Stock Titan Wed, 11 Mar 2026 07
- CNS Pharmaceuticals Unveils Strategic Pivot to Broader Oncology - The Globe and Mail hu, 12 Mar 2026 07
- CNS Pharmaceuticals Announces Reverse Stock Split - Yahoo Finance Fri, 18 Jul 2025 07
- CNS Pharmaceuticals (NASDAQ: CNSP) pivots to neurology and oncology amid going concern risk - Stock Titan ue, 31 Mar 2026 20
- CNSP PE Ratio & Valuation, Is CNSP Overvalued - Intellectia AI ue, 31 Mar 2026 21
- CNSP Stock Upgraded to "Buy" by Maxim Group Analyst | CNSP Stock News - gurufocus.com Fri, 12 Sep 2025 07
- symbol__ Stock Quote Price and Forecast - CNN Fri, 16 Feb 2024 17
- CNSP SEC Filings - CNS Pharmaceuticals 10-K, 10-Q, 8-K Forms - Stock Titan Fri, 20 Mar 2026 00
- CNS Pharmaceuticals (CNSP) Target Price Increased Amid Focus Shi - gurufocus.com hu, 22 May 2025 07
- CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules - Yahoo Finance ue, 13 May 2025 07
- CNS Pharmaceuticals (NASDAQ: CNSP) Announces 1-for-12 Reverse Stock Split Effective July 22 - The Globe and Mail Fri, 18 Jul 2025 07
- CNS Pharmaceuticals Raises $5M in Public Offering - tipranks.com hu, 15 May 2025 07
- Brain cancer drug developer hires veteran surgeon to lead studies - Stock Titan Mon, 02 Mar 2026 08
- Brain cancer drug developer hires CFO, CTO and CBO in strategic reset - Stock Titan ue, 17 Feb 2026 08
- New CNS Pharmaceuticals (NASDAQ: CNSP) team drives strategic pivot - Stock Titan Wed, 11 Mar 2026 07
Insider Transactions
No recent insider transactions.
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
15.99
+7.28%
|
14.90
-21.01%
|
18.87
+23.57%
|
15.27
|
| Research And Development |
|
9.77
+5.19%
|
9.29
-34.09%
|
14.10
+51.56%
|
9.30
|
| Selling General And Administration |
|
6.21
+10.74%
|
5.61
+17.66%
|
4.77
-20.07%
|
5.97
|
| General And Administrative Expense |
|
6.21
+10.74%
|
5.61
+17.66%
|
4.77
-20.07%
|
5.97
|
| Other Gand A |
|
6.21
+10.74%
|
5.61
+17.66%
|
4.77
-20.07%
|
5.97
|
| Total Expenses |
|
15.99
+7.28%
|
14.90
-21.01%
|
18.87
+23.57%
|
15.27
|
| Operating Income |
|
-15.99
-7.28%
|
-14.90
+21.01%
|
-18.87
-23.57%
|
-15.27
|
| Total Operating Income As Reported |
|
-15.99
-7.28%
|
-14.90
+21.01%
|
-18.87
-23.57%
|
-15.27
|
| EBITDA |
|
-15.83
-6.69%
|
-14.84
+21.21%
|
-18.83
-23.45%
|
-15.26
|
| Normalized EBITDA |
|
-15.83
-6.69%
|
-14.84
+21.21%
|
-18.83
-23.45%
|
-15.26
|
| Reconciled Depreciation |
|
0.00
+18.51%
|
0.00
-20.03%
|
0.00
-64.83%
|
0.01
|
| EBIT |
|
-15.84
-6.70%
|
-14.84
+21.21%
|
-18.84
-23.39%
|
-15.27
|
| Net Income |
|
-15.85
-6.68%
|
-14.86
+21.18%
|
-18.85
-23.42%
|
-15.27
|
| Pretax Income |
|
-15.85
-6.68%
|
-14.86
+21.18%
|
-18.85
-23.42%
|
-15.27
|
| Net Non Operating Interest Income Expense |
|
0.14
+213.88%
|
0.04
+217.98%
|
0.01
+297.55%
|
-0.01
|
| Interest Expense Non Operating |
|
0.02
-5.52%
|
0.02
+16.77%
|
0.01
+96.46%
|
0.01
|
| Net Interest Income |
|
0.14
+213.88%
|
0.04
+217.98%
|
0.01
+297.55%
|
-0.01
|
| Interest Expense |
|
0.02
-5.52%
|
0.02
+16.77%
|
0.01
+96.46%
|
0.01
|
| Interest Income Non Operating |
|
0.15
+155.19%
|
0.06
+117.65%
|
0.03
|
0.00
|
| Interest Income |
|
0.15
+155.19%
|
0.06
+117.65%
|
0.03
|
0.00
|
| Other Income Expense |
|
-0.00
|
—
|
—
|
—
|
| Other Non Operating Income Expenses |
|
-0.00
|
—
|
—
|
—
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-15.85
-6.68%
|
-14.86
+21.18%
|
-18.85
-23.42%
|
-15.27
|
| Net Income From Continuing Operation Net Minority Interest |
|
-15.85
-6.68%
|
-14.86
+21.18%
|
-18.85
-23.42%
|
-15.27
|
| Net Income From Continuing And Discontinued Operation |
|
-15.85
-6.68%
|
-14.86
+21.18%
|
-18.85
-23.42%
|
-15.27
|
| Net Income Continuous Operations |
|
-15.85
-6.68%
|
-14.86
+21.18%
|
-18.85
-23.42%
|
-15.27
|
| Normalized Income |
|
-15.85
-6.68%
|
-14.86
+21.18%
|
-18.85
-23.42%
|
-15.27
|
| Net Income Common Stockholders |
|
-15.85
-6.68%
|
-14.86
+21.18%
|
-18.85
-23.42%
|
-15.27
|
| Diluted EPS |
|
—
|
-466.89
+99.49%
|
-91,068.72
+68.40%
|
-288,191.21
|
| Basic EPS |
|
—
|
-466.89
+99.49%
|
-91,068.72
+68.40%
|
-288,191.21
|
| Basic Average Shares |
|
—
|
0.03
+15273.43%
|
0.00
+290.57%
|
0.00
|
| Diluted Average Shares |
|
—
|
0.03
+15273.43%
|
0.00
+290.57%
|
0.00
|
| Diluted NI Availto Com Stockholders |
|
-15.85
-6.68%
|
-14.86
+21.18%
|
-18.85
-23.42%
|
-15.27
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
8.62
-0.89%
|
8.70
+411.56%
|
1.70
-86.97%
|
13.05
|
| Current Assets |
|
8.10
-6.42%
|
8.66
+444.16%
|
1.59
-87.34%
|
12.56
|
| Cash Cash Equivalents And Short Term Investments |
|
7.20
+11.45%
|
6.46
+1077.53%
|
0.55
-94.54%
|
10.06
|
| Cash And Cash Equivalents |
|
7.20
+11.45%
|
6.46
+1077.53%
|
0.55
-94.54%
|
10.06
|
| Cash Financial |
|
—
|
—
|
0.55
-94.54%
|
10.06
|
| Receivables |
|
0.00
-100.00%
|
0.88
|
0.00
|
—
|
| Accounts Receivable |
|
0.00
-100.00%
|
0.88
|
0.00
|
—
|
| Prepaid Assets |
|
—
|
—
|
—
|
2.51
|
| Current Deferred Assets |
|
0.05
+120.41%
|
0.02
-89.83%
|
0.20
|
0.00
|
| Other Current Assets |
|
0.86
-33.82%
|
1.29
+54.12%
|
0.84
-66.54%
|
2.51
|
| Total Non Current Assets |
|
0.52
+1126.97%
|
0.04
-61.31%
|
0.11
-77.55%
|
0.49
|
| Net PPE |
|
0.02
+194.80%
|
0.01
+21.73%
|
0.00
-12.91%
|
0.01
|
| Non Current Deferred Assets |
|
—
|
—
|
—
|
0.00
|
| Non Current Prepaid Assets |
|
0.50
+1280.63%
|
0.04
-65.22%
|
0.10
-78.30%
|
0.48
|
| Total Liabilities Net Minority Interest |
|
4.10
+62.46%
|
2.52
-58.84%
|
6.13
+24.65%
|
4.92
|
| Current Liabilities |
|
4.10
+62.46%
|
2.52
-58.84%
|
6.13
+24.65%
|
4.92
|
| Payables And Accrued Expenses |
|
3.77
+71.61%
|
2.20
-62.31%
|
5.83
+29.31%
|
4.51
|
| Payables |
|
—
|
—
|
—
|
3.68
|
| Accounts Payable |
|
—
|
—
|
—
|
3.68
|
| Current Accrued Expenses |
|
—
|
—
|
—
|
0.83
|
| Current Debt And Capital Lease Obligation |
|
0.33
+0.77%
|
0.33
+8.40%
|
0.30
-26.63%
|
0.41
|
| Current Debt |
|
0.33
+0.77%
|
0.33
+8.40%
|
0.30
-26.63%
|
0.41
|
| Total Non Current Liabilities Net Minority Interest |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Stockholders Equity |
|
4.52
-26.78%
|
6.18
+239.36%
|
-4.43
-154.50%
|
8.13
|
| Common Stock Equity |
|
4.52
-26.78%
|
6.18
+239.36%
|
-4.43
-154.50%
|
8.13
|
| Capital Stock |
|
0.00
+436.44%
|
0.00
+5800.00%
|
0.00
-99.88%
|
0.00
|
| Common Stock |
|
0.00
+436.44%
|
0.00
+5800.00%
|
0.00
-99.88%
|
0.00
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
0.62
+426.58%
|
0.12
+56806.28%
|
0.00
+290.57%
|
0.00
|
| Ordinary Shares Number |
|
0.62
+426.58%
|
0.12
+56806.28%
|
0.00
+290.57%
|
0.00
|
| Additional Paid In Capital |
|
104.80
+15.67%
|
90.60
+39.10%
|
65.13
+10.69%
|
58.85
|
| Retained Earnings |
|
-100.28
-18.77%
|
-84.42
-21.36%
|
-69.57
-37.17%
|
-50.72
|
| Total Equity Gross Minority Interest |
|
4.52
-26.78%
|
6.18
+239.36%
|
-4.43
-154.50%
|
8.13
|
| Total Capitalization |
|
4.52
-26.78%
|
6.18
+239.36%
|
-4.43
-154.50%
|
8.13
|
| Working Capital |
|
4.00
-34.76%
|
6.13
+235.06%
|
-4.54
-159.41%
|
7.64
|
| Invested Capital |
|
4.85
-25.40%
|
6.50
+257.40%
|
-4.13
-148.36%
|
8.54
|
| Total Debt |
|
0.33
+0.77%
|
0.33
+8.40%
|
0.30
-26.63%
|
0.41
|
| Net Tangible Assets |
|
4.52
-26.78%
|
6.18
+239.36%
|
-4.43
-154.50%
|
8.13
|
| Tangible Book Value |
|
4.52
-26.78%
|
6.18
+239.36%
|
-4.43
-154.50%
|
8.13
|
| Current Notes Payable |
|
0.33
+0.77%
|
0.33
+8.40%
|
0.30
-26.63%
|
0.41
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-13.81
+19.30%
|
-17.11
-21.03%
|
-14.14
-33.93%
|
-10.56
|
| Cash Flow From Continuing Operating Activities |
|
-13.81
+19.30%
|
-17.11
-21.03%
|
-14.14
-33.93%
|
-10.56
|
| Net Income From Continuing Operations |
|
-15.85
-6.68%
|
-14.86
+21.18%
|
-18.85
-23.42%
|
-15.27
|
| Depreciation Amortization Depletion |
|
0.00
+18.51%
|
0.00
-20.03%
|
0.00
-64.83%
|
0.01
|
| Depreciation |
|
0.00
+18.51%
|
0.00
-20.03%
|
0.00
-64.83%
|
0.01
|
| Depreciation And Amortization |
|
0.00
+18.51%
|
0.00
-20.03%
|
0.00
-64.83%
|
0.01
|
| Other Non Cash Items |
|
—
|
0.60
|
—
|
—
|
| Stock Based Compensation |
|
0.19
-77.62%
|
0.84
-16.72%
|
1.01
-16.26%
|
1.20
|
| Asset Impairment Charge |
|
—
|
—
|
0.00
-100.00%
|
0.33
|
| Operating Gains Losses |
|
0.00
+1446.84%
|
-0.00
-138.15%
|
0.00
-83.99%
|
0.00
|
| Gain Loss On Sale Of PPE |
|
0.00
+1446.84%
|
-0.00
-138.15%
|
0.00
-83.99%
|
0.00
|
| Change In Working Capital |
|
1.85
+149.95%
|
-3.69
-199.86%
|
3.70
+16.90%
|
3.16
|
| Change In Prepaid Assets |
|
0.30
+604.90%
|
-0.06
-102.52%
|
2.38
+176.28%
|
0.86
|
| Change In Payables And Accrued Expense |
|
1.54
+142.45%
|
-3.63
-374.91%
|
1.32
-42.62%
|
2.30
|
| Change In Accrued Expense |
|
—
|
—
|
—
|
0.60
|
| Change In Payable |
|
—
|
—
|
—
|
1.70
|
| Change In Account Payable |
|
—
|
—
|
—
|
1.70
|
| Investing Cash Flow |
|
-0.02
-333.98%
|
-0.00
-7.36%
|
-0.00
+11.78%
|
-0.00
|
| Cash Flow From Continuing Investing Activities |
|
-0.02
-333.98%
|
-0.00
-7.36%
|
-0.00
+11.78%
|
-0.00
|
| Net PPE Purchase And Sale |
|
-0.02
-333.98%
|
-0.00
-7.36%
|
-0.00
+11.78%
|
-0.00
|
| Purchase Of PPE |
|
-0.02
-333.98%
|
-0.00
-7.36%
|
-0.00
+11.78%
|
-0.00
|
| Capital Expenditure |
|
-0.02
-333.98%
|
-0.00
-7.36%
|
-0.00
+11.78%
|
-0.00
|
| Financing Cash Flow |
|
14.57
-36.74%
|
23.03
+396.63%
|
4.64
-70.30%
|
15.61
|
| Cash Flow From Continuing Financing Activities |
|
14.57
-36.74%
|
23.03
+396.63%
|
4.64
-70.30%
|
15.61
|
| Net Issuance Payments Of Debt |
|
-0.30
+1.08%
|
-0.30
+31.44%
|
-0.44
-2.58%
|
-0.43
|
| Repayment Of Debt |
|
-0.30
+1.08%
|
-0.30
+31.44%
|
-0.44
-2.58%
|
-0.43
|
| Long Term Debt Payments |
|
—
|
—
|
—
|
—
|
| Net Long Term Debt Issuance |
|
—
|
—
|
—
|
—
|
| Short Term Debt Payments |
|
-0.30
+1.08%
|
-0.30
+31.44%
|
-0.44
-2.58%
|
-0.43
|
| Net Short Term Debt Issuance |
|
-0.30
+1.08%
|
-0.30
+31.44%
|
-0.44
-2.58%
|
-0.43
|
| Net Common Stock Issuance |
|
14.04
-39.92%
|
23.38
+908.65%
|
2.32
-85.55%
|
16.04
|
| Common Stock Payments |
|
-0.00
|
0.00
|
—
|
—
|
| Repurchase Of Capital Stock |
|
-0.00
|
0.00
|
—
|
—
|
| Proceeds From Stock Option Exercised |
|
0.00
-82.99%
|
0.02
-99.28%
|
2.96
+108211.59%
|
0.00
|
| Net Other Financing Charges |
|
0.82
+1326.15%
|
-0.07
+67.10%
|
-0.20
|
—
|
| Changes In Cash |
|
0.74
-87.49%
|
5.91
+162.19%
|
-9.51
-288.22%
|
5.05
|
| Beginning Cash Position |
|
6.46
+1077.53%
|
0.55
-94.54%
|
10.06
+100.93%
|
5.00
|
| End Cash Position |
|
7.20
+11.45%
|
6.46
+1077.53%
|
0.55
-94.54%
|
10.06
|
| Free Cash Flow |
|
-13.83
+19.21%
|
-17.12
-21.02%
|
-14.14
-33.91%
|
-10.56
|
| Interest Paid Supplemental Data |
|
0.02
+12.27%
|
0.01
-1.49%
|
0.01
+70.56%
|
0.01
|
| Income Tax Paid Supplemental Data |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Common Stock Issuance |
|
14.05
-39.91%
|
23.38
+908.65%
|
2.32
-85.55%
|
16.04
|
| Issuance Of Capital Stock |
|
14.05
-39.91%
|
23.38
+908.65%
|
2.32
-85.55%
|
16.04
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 10-K2026-03-31 View
- 8-K2026-03-11 View
- 42026-03-04 View
- 42026-03-04 View
- 8-K2026-03-02 View
- 8-K2026-02-17 View
- 42026-01-02 View
- 8-K2025-12-17 View
- 8-K2025-11-21 View
- 42025-11-19 View
- 42025-11-19 View
- 42025-11-19 View
- 42025-11-19 View
- 42025-11-19 View
- 42025-11-19 View
- 42025-11-19 View
- 10-Q2025-11-14 View
- 10-Q2025-08-14 View
- 8-K2025-07-22 View
- 8-K2025-07-15 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|